KR20160106175A - 에놀라아제 1 조성물들 및 이의 용도 - Google Patents

에놀라아제 1 조성물들 및 이의 용도 Download PDF

Info

Publication number
KR20160106175A
KR20160106175A KR1020167022300A KR20167022300A KR20160106175A KR 20160106175 A KR20160106175 A KR 20160106175A KR 1020167022300 A KR1020167022300 A KR 1020167022300A KR 20167022300 A KR20167022300 A KR 20167022300A KR 20160106175 A KR20160106175 A KR 20160106175A
Authority
KR
South Korea
Prior art keywords
eno1
subject
blood glucose
pharmaceutical composition
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167022300A
Other languages
English (en)
Korean (ko)
Inventor
니븐 라진 나레인
랑가프라사드 사란가라잔
비벡 케이. 비쉬누다스
스테판 제스타
인슈 징
Original Assignee
버그 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 버그 엘엘씨 filed Critical 버그 엘엘씨
Publication of KR20160106175A publication Critical patent/KR20160106175A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K47/48192—
    • A61K47/48246—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
KR1020167022300A 2014-01-13 2015-01-13 에놀라아제 1 조성물들 및 이의 용도 Withdrawn KR20160106175A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461926913P 2014-01-13 2014-01-13
US61/926,913 2014-01-13
US201462009783P 2014-06-09 2014-06-09
US62/009,783 2014-06-09
US201562100881P 2015-01-07 2015-01-07
US62/100,881 2015-01-07
PCT/US2015/011275 WO2015106295A2 (en) 2014-01-13 2015-01-13 Enolase 1 (eno1) compositions and uses thereof

Publications (1)

Publication Number Publication Date
KR20160106175A true KR20160106175A (ko) 2016-09-09

Family

ID=53524434

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167022300A Withdrawn KR20160106175A (ko) 2014-01-13 2015-01-13 에놀라아제 1 조성물들 및 이의 용도

Country Status (14)

Country Link
US (4) US10188708B2 (cg-RX-API-DMAC7.html)
EP (2) EP3094379A4 (cg-RX-API-DMAC7.html)
JP (2) JP6644006B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160106175A (cg-RX-API-DMAC7.html)
CN (3) CN106102835B (cg-RX-API-DMAC7.html)
AU (2) AU2015204452A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016016153A2 (cg-RX-API-DMAC7.html)
CA (2) CA2936691A1 (cg-RX-API-DMAC7.html)
EA (1) EA201691420A1 (cg-RX-API-DMAC7.html)
HK (1) HK1231425A1 (cg-RX-API-DMAC7.html)
IL (1) IL246720A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016009102A (cg-RX-API-DMAC7.html)
SG (1) SG11201605698XA (cg-RX-API-DMAC7.html)
WO (2) WO2015106295A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3094379A4 (en) * 2014-01-13 2017-06-28 Berg LLC Enolase 1 (eno1) compositions and uses thereof
CN107847560A (zh) * 2015-06-22 2018-03-27 博格有限责任公司 包括eno1的组合物以及其在治疗肥胖症或超重和减少体重增加的方法中的用途
WO2017062363A1 (en) * 2015-10-05 2017-04-13 Joslin Diabetes Center Methods of use of betatrophin
AU2017278261A1 (en) 2016-06-05 2019-01-31 Berg Llc Systems and methods for patient stratification and identification of potential biomarkers
CN107991493B (zh) * 2017-11-22 2020-03-31 中国医科大学附属第一医院 抗eno1自身抗体在对ait孕妇筛查和预测流产风险中的应用
CN112111462B (zh) * 2020-09-14 2022-08-23 兰州大学 烯醇化酶eno1单克隆抗体及其应用
CA3236326A1 (en) * 2021-11-26 2023-06-01 Hunilife Biotechnology, Inc. Methods to regulate glycolysis via targeting extracellular alpha-enolase for treating human diseases
CN114533902A (zh) * 2022-02-28 2022-05-27 河南师范大学 一种过表达lrrc15基因的质粒载体及其制备方法和应用
CN115786317A (zh) * 2022-12-12 2023-03-14 江苏三联生物工程股份有限公司 重组神经元特异性烯醇化酶及其制备方法与应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233126T2 (de) 1992-09-25 2004-04-15 Neorx Corp., Seattle Therapeutischer inhibitor der vaskulären glatten muskelzellen
AU4278296A (en) 1994-10-25 1996-05-15 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US20030044795A1 (en) 1996-09-06 2003-03-06 Inger Byrajalsen Biochemical markers of the human endometrium
US7078375B1 (en) 1996-10-25 2006-07-18 Peter Mose Larsen Diabetes-mediating proteins and therapeutic uses thereof
US6329501B1 (en) 1997-05-29 2001-12-11 Auburn University Methods and compositions for targeting compounds to muscle
IL148225A0 (en) 1999-09-01 2002-09-12 Subsidiary No 3 Inc Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO2001016323A2 (en) 1999-09-01 2001-03-08 Subsidiary N0.3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO2001030973A2 (en) 1999-10-25 2001-05-03 Princeton University Genetic sequences associated with neural cell proliferation and disease
US20030166549A1 (en) * 2000-02-02 2003-09-04 Klaus Schughart Targeting peptides
US20030203372A1 (en) 2000-12-08 2003-10-30 Ward Neil Raymond Analysis method
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
US20040058326A1 (en) 2001-07-27 2004-03-25 Brooksbank Robert Alan Identification and use of molecules implicated in pain
US20050191627A1 (en) 2001-09-28 2005-09-01 Incyte Corporation Enzymes
WO2003064501A1 (en) 2002-01-31 2003-08-07 Clarke Slemon Conformationally restricted compounds as dendrimer cores
US20050222023A1 (en) 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
JP2004081111A (ja) 2002-08-27 2004-03-18 Yamaguchi Technology Licensing Organization Ltd 虚血性心疾患の治療薬として新規活性を有するα−エノラーゼおよびその利用法
CA2503748A1 (en) 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CN101518535A (zh) * 2002-12-06 2009-09-02 法布罗根股份有限公司 脂肪调节
AU2003294828A1 (en) 2002-12-17 2004-07-09 Sinogenomax Co. Ltd. Chinese National Human Genomecenter Specific markers for pancreatic cancer
AU2003300178A1 (en) 2002-12-30 2004-07-29 Ppd Development, Lp Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO2004084950A2 (en) 2003-03-24 2004-10-07 Case Western Reserve University Cell targeting methods and compositions
US7473531B1 (en) 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2005073621A (ja) 2003-09-01 2005-03-24 Japan Science & Technology Agency 脳腫瘍マーカーと脳腫瘍の診断方法
CA2540529C (en) 2003-10-03 2012-03-13 Vib Vzw Means and methods for the recruitment and identification of stem cells
US8133733B2 (en) * 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
EP1664775A4 (en) 2004-07-06 2008-03-12 Kuhnil Pharm Co Ltd COMPOSITION FOR THE DIAGNOSIS OF RETINAL VASCULAR DISEASE COMPRISING ALDOLASE AND DIAGNOSTIC METHOD USING THE SAME
WO2007046818A2 (en) 2004-11-16 2007-04-26 Board Of Regents, The University Of Texas System Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display
EP1843781B1 (en) * 2005-01-03 2015-03-18 Jeon, Sook-yeong Composition for prevention, treatment and diagnosis of chronic inflammatory airway diseases
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
JP5137814B2 (ja) 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート
US20070248628A1 (en) 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
TWI304443B (en) 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
WO2008012362A2 (en) 2006-07-27 2008-01-31 Oxford Genome Sciences (Uk) Ltd New protein isoforms and uses thereof
ATE542831T1 (de) 2006-09-29 2012-02-15 Ribovax Biotechnologies Sa Neue antigene und antikörper, die mit adenokarzinomen des pankreasgangs assoziiert sind
US20100047256A1 (en) 2007-01-25 2010-02-25 Imperial Innovations Limited Methods
WO2008134761A2 (en) 2007-04-30 2008-11-06 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
CN103212085A (zh) * 2007-07-12 2013-07-24 普罗森那技术公司 用于使化合物靶向多种选定器官或组织的分子
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
JP5429707B2 (ja) 2008-03-27 2014-02-26 国立大学法人群馬大学 微粒子およびその製造方法
US20110130346A1 (en) * 2008-05-30 2011-06-02 Isis Innovation Limited Peptide conjugates for delvery of biologically active compounds
JP2011528557A (ja) 2008-07-18 2011-11-24 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 過体重動物と関連する障害を治療するための組成物および方法
EP2194382A1 (en) 2008-12-03 2010-06-09 Universität des Saarlandes An in-vitro method or assay for detecting a tumor or a cancerous disease by screening for antibodies
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
IT1398782B1 (it) 2009-09-11 2013-03-18 Novelli Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi.
US20120309684A1 (en) 2009-11-30 2012-12-06 Isis Innovation Limited Conjugates for delivery of biologically active compounds
WO2011072290A2 (en) * 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates
WO2011147981A2 (en) 2010-05-28 2011-12-01 Mind-Nrg Sa Neuregulin isoforms, neuregulin polypeptides and uses thereof
WO2012065034A1 (en) 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
ES2560012T3 (es) * 2011-05-10 2016-02-17 Institut National De La Santé Et De La Recherche Médicale (Inserm) Métodos y composiciones farmacéuticas para el tratamiento de enfermedades autoinmunitarias
GB201113814D0 (en) 2011-08-10 2011-09-28 Proteome Sciences R & D Gmbh & Co Kg Materials and methods for determining sensitivity potential of compounds
EP2751128B1 (en) 2011-08-30 2021-03-03 United Kingdom Research and Innovation Cell-penetrating peptides having a central hydrophobic domain
CN109276717B (zh) 2011-12-14 2022-04-12 得克萨斯系统大学董事会 用于癌症疗法的连带基因失活生物标志和靶标
WO2014018851A1 (en) 2012-07-26 2014-01-30 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
EP2914247A4 (en) 2012-10-30 2016-06-29 Particle Sciences Inc DRUG DELIVERY PARTICLE FORMULATIONS WITH TARGETING ELEMENTS
EP3094379A4 (en) * 2014-01-13 2017-06-28 Berg LLC Enolase 1 (eno1) compositions and uses thereof
CN107847560A (zh) 2015-06-22 2018-03-27 博格有限责任公司 包括eno1的组合物以及其在治疗肥胖症或超重和减少体重增加的方法中的用途
WO2017011836A1 (en) 2015-07-16 2017-01-19 Berg Llc Enolase 1 (eno1) compositions and uses thereof

Also Published As

Publication number Publication date
WO2015106296A8 (en) 2015-08-20
JP2017508000A (ja) 2017-03-23
EP3094379A4 (en) 2017-06-28
US20190307864A1 (en) 2019-10-10
CN106659766B (zh) 2025-03-28
CN106102835B (zh) 2020-11-03
AU2015204451A1 (en) 2016-07-28
US20150359861A1 (en) 2015-12-17
CA2936694A1 (en) 2015-07-16
HK1231394A1 (en) 2017-12-22
EP3094341A1 (en) 2016-11-23
US10188708B2 (en) 2019-01-29
SG11201605698XA (en) 2016-08-30
EP3094341A4 (en) 2017-11-01
JP6629234B2 (ja) 2020-01-15
WO2015106296A1 (en) 2015-07-16
JP2017509690A (ja) 2017-04-06
WO2015106295A3 (en) 2015-11-05
CN112336851A (zh) 2021-02-09
MX2016009102A (es) 2016-09-09
US10188707B2 (en) 2019-01-29
AU2015204452A1 (en) 2016-08-11
WO2015106295A2 (en) 2015-07-16
EP3094379A2 (en) 2016-11-23
US11224641B2 (en) 2022-01-18
CN106102835A (zh) 2016-11-09
EP3094341B1 (en) 2019-10-02
JP6644006B2 (ja) 2020-02-12
CA2936691A1 (en) 2015-07-16
EA201691420A1 (ru) 2016-12-30
BR112016016153A2 (pt) 2017-12-12
CN106659766A (zh) 2017-05-10
HK1231425A1 (zh) 2017-12-22
US20150361409A1 (en) 2015-12-17
IL246720A0 (en) 2016-08-31
US20190307863A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
US11224641B2 (en) Enolase 1 (ENO1) compositions and uses thereof
US20230414717A1 (en) Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
EP3645736B1 (en) Method for determining the risk to develop type 1 diabetes
WO2003102163A2 (en) Methods of diagnosing and treating diabetes and insulin resistance
US20130210039A1 (en) Blood insulin resistance and diabetes marker progranulin, method for analyzing concentration of progranulin in blood sample, and method for screening for substance that improves insulin resistance and improves or suppresses diabetes
US20060292563A1 (en) Methods of diagnosing & treating diabetes and insulin resistance
US20110214193A1 (en) Biomarker for microdomain disease
HK1231394B (en) Enolase 1 (eno1) compositions and uses thereof
US20060074018A1 (en) Methods of diagnosing & treating diabetes and insulin resistance
Grunseich et al. A randomized, placebo-controlled study to evaluate the safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy
JP2022500623A (ja) 肝疾患の診断方法
JP2008502909A (ja) 糖尿病およびインスリン抵抗性の診断および治療の方法
Wu Mass spectrometry for measuring protein secretion from insulin sensitive tissues during obesity

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160816

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid